Therapeutic innovations in inflammatory bowel diseases

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 1, 2016, Pages 49-58

  Vanhove, W ^a   Nys, K ^a   Vermeire, S ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23 ANTIBODY; JANUS KINASE; JANUS KINASE INHIBITOR; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE; MONOCLONAL ANTIBODY;

ARTICLE; CELL THERAPY; CLINICAL EVALUATION; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE MIGRATION; NONHUMAN; PATHOGENESIS; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BIOLOGICAL THERAPY; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; CELL- AND TISSUE-BASED THERAPY; CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; JANUS KINASES; LEUKOCYTES; MODELS, BIOLOGICAL; OLIGONUCLEOTIDES, ANTISENSE; PRECISION MEDICINE;

EID: 84955293544     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.286     Document Type: Article

References (100)

1. Braegger, C.P., Nicholls, S., Murch, S.H., Stephens, S., &, MacDonald, T.T., Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339, 89-91 (1992).
2. MacDonald, T.T., Hutchings, P., Choy, M.Y., Murch, S., &, Cooke, A., Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin. Exp. Immunol. 81, 301-305 (1990).
3. Reinecker, H.C., et al,. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 94, 174-181 (1993).
4. Murch, S.H., Lamkin, V.A., Savage, M.O., Walker-Smith, J.A., &, MacDonald, T.T., Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32, 913-917 (1991).
5. Targan, S.R., et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337, 1029-1035 (1997).
6. Rutgeerts, P., et al,. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117, 761-769 (1999).
7. D'haens, G., et al,. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116, 1029-1034 (1999).
8. Hanauer, S.B., et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002).
9. Järnerot, G., et al,. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128, 1805-1811 (2005).
10. Rutgeerts, P., et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462-2476 (2005).
11. Reinisch, W., et al,. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and-2 extension studies. Inflamm. Bowel Dis. 18, 201-211 (2012).
12. Hazlewood, G.S., et al,. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology 148, 344-354.e5; quiz e14-e15 (2015).
13. Song, Y.-N., &, Zheng, P., Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: a systematic review and meta-analysis of published randomized controlled trials. J. Food Drug Anal. 23, 1-10 (2015).
14. Cleynen, I., et al,. Characteristics of anti-TNF-associated skin lesions in inflammatory bowel disease patients: a cohort study. Ann. Intern. Med. (2015); e-pub ahead of print.
15. Jostins, L., et al,. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012).
16. Strober, W., &, Fuss, I.J., Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140, 1756-1767 (2011).
17. Sandborn, W.J., et al,. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135, 1130-1141 (2008).
18. Sandborn, W.J., et al,. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367, 1519-1528 (2012).
19. Tuskey, A., &, Behm, B.W., Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease. Clin. Exp. Gastroenterol. 7, 173-179 (2014).
20. Sansõ Sureda, A., Rocamora Durán, V., Sapinã Camarõ, A., Royo Escosa, V., &, Bosque Lõpez, M.J., Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis [in Spanish]. Gastroenterol. Hepatol. 34, 546-550 (2011).
21. Hueber, W., et al,. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693-1700 (2012).
22. Murray, P.J., The JAK-STAT signaling pathway: input and output integration. J. Immunol. 178, 2623-2629 (2007).
23. Coskun, M., Salem, M., Pedersen, J., &, Nielsen, O.H., Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol. Res. 76, 1-8 (2013).
24. Ghoreschi, K., et al,. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186, 4234-4243 (2011).
25. Merciris, D., et al,. P072. GLPG0634, the first selective JAK1 inhibitor, shows strong activity in the mouse DSS-colitis model. European Crohn's and Colitis Organisation. Poster presentation: Basic Science (2014).
26. Sandborn, W.J., et al,. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616-624 (2012).
27. Sandborn, W.J., et al,. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 12, 1485-1493.e2 (2014).
28. Vanhoutte, F.P., Mazur, M., Namour, F., van der Aa, A., Wigerinck, P., &, van't Klooster, G.A.E., [OP0263] Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial. Ann. Rheum. Dis. 71 (suppl. 3), 145 (2012).
29. Gasche, C., Lomer, M.C., Cavill, I., &, Weiss, G., Iron, anaemia, and inflammatory bowel diseases. Gut 53, 1190-1197 (2004).
30. Koizumi, M., King, N., Lobb, R., Benjamin, C., &, Podolsky, D.K., Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 103, 840-847 (1992).
31. Souza, H.S., Elia, C.C., Spencer, J., &, MacDonald, T.T., Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 45, 856-863 (1999).
32. Podolsky, D.K., et al,. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J. Clin. Invest. 92, 372-380 (1993).
33. Hesterberg, P.E., et al,. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 111, 1373-1380 (1996).
34. Sandborn, W.J., et al,. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353, 1912-1925 (2005).
35. Targan, S.R., et al,. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132, 1672-1683 (2007).
36. Van Assche, G., et al,. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362-368 (2005).
37. Bloomgren, G., et al,. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880 (2012).
38. Feagan, B.G., et al,. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699-710 (2013).
39. Sandborn, W.J., et al,. Vedolizumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 369, 711-721 (2013).
40. Sands, B.E., et al,. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147, 618-627.e3 (2014).
41. Bryant, R.V., Sandborn, W.J., &, Travis, S.P., Introducing vedolizumab to clinical practice: who, when, and how? J. Crohns Colitis 9, 356-366 (2015).
42. Vermeire, S., et al,. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 384, 309-318 (2014).
43. Monteleone, G., Pallone, F., &, MacDonald, T.T., Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol. 25, 513-517 (2004).
44. Monteleone, G., Boirivant, M., Pallone, F., &, MacDonald, T.T., TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol. 1 (suppl. 1), S50-S53 (2008).
45. Monteleone, G., Kumberova, A., Croft, N.M., McKenzie, C., Steer, H.W., &, MacDonald, T.T., Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108, 601-609 (2001).
46. Boirivant, M., et al,. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 131, 1786-1798 (2006).
47. Monteleone, G., et al,. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N. Engl. J. Med. 372, 1104-1113 (2015).
48. Vermeire, S., Oral SMAD7 antisense drug for Crohn's disease. N. Engl. J. Med. 372, 1166-1167 (2015).
49. Zorzi, F., et al,. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol. Ther. 36, 850-857 (2012).
50. van Deventer, S.J., Wedel, M.K., Baker, B.F., Xia, S., Chuang, E., &, Miner, P.B. Jr., A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol. Ther. 23, 1415-1425 (2006).
51. Miner, P.B. Jr, Wedel, M.K., Xia, S., &, Baker, B.F., Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol. Ther. 23, 1403-1413 (2006).
52. Miner, P., Wedel, M., Bane, B., &, Bradley, J., An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol. Ther. 19, 281-286 (2004).
53. Yacyshyn, B., Chey, W.Y., Wedel, M.K., Yu, R.Z., Paul, D., &, Chuang, E., A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin. Gastroenterol. Hepatol. 5, 215-220 (2007).
54. Monteith, D.K., et al,. Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol. Pathol. 27, 307-317 (1999).
55. van Poelgeest, E.P., et al,. Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am. J. Kidney Dis. 62, 796-800 (2013).
56. Duijvestein, M., van den Brink, G.R., &, Hommes, D.W., Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. J. Crohns Colitis 2, 99-106 (2008).
57. Hommes, D.W., et al,. Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease. J. Crohns Colitis 5, 543-549 (2011).
58. Molendijk, I., et al,. Immunomodulatory effects of mesenchymal stromal cells in Crohn's disease. J. Allergy (Cairo) 2012, 187408 (2012).
59. Duijvestein, M., et al,. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 59, 1662-1669 (2010).
60. Forbes, G.M., et al,. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin. Gastroenterol. Hepatol. 12, 64-71 (2014).
61. Dave, M., Mehta, K., Luther, J., Baruah, A., Dietz, A.B., &, Faubion, W.A. Jr., Mesenchymal stem cell therapy for inflammatory bowel disease: a systematic review and meta-analysis. Inflamm. Bowel Dis. 21, 2696-2707 (2015).
62. Garcia-Olmo, D., et al,. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis. Colon Rectum. 52, 79-86 (2009).
63. de la Portilla, F., Alba, F., Garciá-Olmo, D., Herreriás, J.M., González, F.X., &, Galindo, A., Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int. J. Colorectal Dis. 28, 313-323 (2013).
64. Desreumaux, P., et al,. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 143, 1207-1217.e1-2 (2012).
65. Xavier, R.J., &, Podolsky, D.K., Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427-434 (2007).
66. Hugot, J.P., et al,. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
67. Ogura, Y., et al,. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
68. Huynh, D., et al,. Colony stimulating factor-1 dependence of paneth cell development in the mouse small intestine. Gastroenterology 137, 136-144 (2009).
69. Wehkamp, J., et al,. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc. Natl. Acad. Sci. USA 102, 18129-18134 (2005).
70. Pastorelli, L., De Salvo, C., Mercado, J.R., Vecchi, M., &, Pizarro, T.T., Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front. Immunol. 4, 280 (2013).
71. Groschwitz, K.R., &, Hogan, S.P., Intestinal barrier function: molecular regulation and disease pathogenesis. J. Allergy Clin. Immunol. 124, 3-20; quiz 21-22 (2009).
72. Hollander, D., Vadheim, C.M., Brettholz, E., Petersen, G.M., Delahunty, T., &, Rotter, J.I., Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann. Intern. Med. 105, 883-885 (1986).
73. Irvine, E.J., &, Marshall, J.K., Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 119, 1740-1744 (2000).
74. Kim, I., Xu, W., &, Reed, J.C., Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 7, 1013-1030 (2008).
75. Kaser, A., Flak, M.B., Tomczak, M.F., &, Blumberg, R.S., The unfolded protein response and its role in intestinal homeostasis and inflammation. Exp. Cell Res. 317, 2772-2779 (2011).
76. Mizushima, N., &, Komatsu, M., Autophagy: renovation of cells and tissues. Cell 147, 728-741 (2011).
77. Henckaerts, L., et al,. Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease. Inflamm. Bowel Dis. 17, 1392-1397 (2011).
78. Hoefkens, E., et al,. Genetic association and functional role of Crohn disease risk alleles involved in microbial sensing, autophagy, and endoplasmic reticulum (ER) stress. Autophagy 9, 2046-2055 (2013).
79. Cao, S.S., et al,. The unfolded protein response and chemical chaperones reduce protein misfolding and colitis in mice. Gastroenterology 144, 989-1000 e6 (2013).
80. Laukens, D., et al,. Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death. Lab. Invest. 94, 1419-1430 (2014).
81. Nys, K., Agostinis, P., &, Vermeire, S., Autophagy: a new target or an old strategy for the treatment of Crohn's disease? Nat. Rev. Gastroenterol. Hepatol. 10, 395-401 (2013).
82. Massey, D.C., Bredin, F., &, Parkes, M., Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 57, 1294-1296 (2008).
83. Mutalib, M., et al,. The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children. J. Crohns Colitis 8, 1730-1734 (2014).
84. Madsen, K.L., Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse. Clin. Invest. Med. 24, 250-257 (2001).
85. Rutgeerts, P., et al,. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 338, 771-774 (1991).
86. Arumugam, M., et al,. Enterotypes of the human gut microbiome. Nature 473, 174-180 (2011).
87. Sokol, H., et al,. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 105, 16731-16736 (2008).
88. Joossens, M., et al,. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 60, 631-637 (2011).
89. Barnich, N., et al,. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J. Clin. Invest. 117, 1566-1574 (2007).
90. Machiels, K., et al,. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63, 1275-1283 (2014).
91. Gevers, D., et al,. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 15, 382-392 (2014).
92. Vande Casteele, N., et al,. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148, 1320-1329.e3 (2015).
93. Chouchana, L., Narjoz, C., Beaune, P., Loriot, M.A., &, Roblin, X., Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol. Ther. 35, 15-36 (2012).
94. Chang, J.C., et al,. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
95. Watanabe, T., et al,. Gene expression signature for recurrence in stage III colorectal cancers. Cancer 115, 283-292 (2009).
96. De Roock, W., et al,. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753-762 (2010).
97. Lee, J.C., et al,. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J. Clin. Invest. 121, 4170-4179 (2011).
98. Arijs, I., et al,. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One 4, e7984 (2009).
99. Arijs, I., et al,. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm. Bowel Dis. 16, 2090-2098 (2010).
100. Sandborn, W.J., Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 135, 1442-1447 (2008).